Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
08
07
2020
accepted:
17
11
2020
entrez:
29
3
2021
pubmed:
30
3
2021
medline:
30
3
2021
Statut:
epublish
Résumé
UK management costs for COPD, estimated at £1.9 billion/year, are rising. In the FULFIL (Lung Function and Quality of Life Assessment in Chronic Obstructive Pulmonary Disease with Closed Triple Therapy) study, single-inhaler triple therapy with fluticasone furoate/umeclidinium/vilanterol (100/62.5/25 µg) improved clinical outcomes
Identifiants
pubmed: 33778055
doi: 10.1183/23120541.00480-2020
pii: 00480-2020
pmc: PMC7983252
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright ©ERS 2021.
Déclaration de conflit d'intérêts
Conflict of interest: E. Fenwick reports GSK provided funds to ICON plc to build the model and conduct the analysis in the present study. Conflict of interest: A. Martin is an employee of GlaxoSmithKline. Conflict of interest: M. Schroeder was an employee and shareholder of GlaxoSmithKline plc at the time of the study. Conflict of interest: S.J. Mealing reports grants from GlaxoSmithKline plc during the conduct of the study and outside the submitted work, all of which were paid to ICON Health Economics. Conflict of interest: O. Solanke reports personal fees from GlaxoSmithKline plc during the conduct of the study. Conflict of interest: N. Risebrough has nothing to disclose. Conflict of interest: A.S. Ismaila reports the study was funded GlaxoSmithKline, of which A.S. Ismaila is an employee and shareholder. A.S. Ismaila is also an unpaid, part-time professor at McMaster University.
Références
Respir Med. 2011 Dec;105(12):1872-84
pubmed: 21852081
Value Health. 2014 Nov;17(7):A560-1
pubmed: 27201846
N Engl J Med. 2008 Oct 9;359(15):1543-54
pubmed: 18836213
Lung. 2017 Jun;195(3):281-288
pubmed: 28255905
Sci Rep. 2016 Sep 01;6:31893
pubmed: 27583987
Am J Respir Crit Care Med. 2017 Aug 15;196(4):438-446
pubmed: 28375647
Value Health. 2017 Mar;20(3):397-403
pubmed: 28292484
Med Decis Making. 2017 May;37(4):469-480
pubmed: 27317436
Eur Respir J. 2009 Sep;34(3):641-7
pubmed: 19443528
Eur Respir J. 2014 Apr;43(4):993-1002
pubmed: 24176990
Chest. 2006 Oct;130(4):1117-28
pubmed: 17035446
Med Decis Making. 2017 May;37(4):453-468
pubmed: 26449490
Value Health. 2005 Jan-Feb;8(1):32-46
pubmed: 15841892
Eur Respir J. 2004 Aug;24(2):206-10
pubmed: 15332386
Eur Respir Rev. 2018 Oct 3;27(149):
pubmed: 30282634
N Engl J Med. 2007 Feb 22;356(8):775-89
pubmed: 17314337